Search

Your search keyword '"Severe haemophilia A"' showing total 13 results
Start Over Descriptor "Severe haemophilia A" Journal value in health
13 results on '"Severe haemophilia A"'

1. PRO4 Matching-Adjusted Indirect Comparisons of Annualized Bleeding RATE and Treatment Utilization between Extended Half-Life Recombinant Factor VIII Products, Bay 94-9027 and Turoctocog ALFA Pegol, for Prophylaxis of Severe Haemophilia a

Author

P. Vashi, M.E. Mancuso, Lorenzo G. Mantovani, Katharine Batt, R. Majewska, and R. Klamroth

Subjects
Matching (statistics), Pediatrics, medicine.medical_specialty, Treatment utilization, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, Severe haemophilia A, Turoctocog alfa, business, Recombinant factor viii
Published
2020

2. PRO38 LONG-TERM Outcomes of Previously-Treated Adult and Adolescent Patients with Severe Haemophilia a Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a UK Perspective

Author

T. Morton, G. Benson, H. Thomas, and X.Y. Lee

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, Long term outcomes, Economic analysis, Medicine, Severe haemophilia A, business, Previously treated
Published
2020

4. PRO104 DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Author

I. Cuervo-Arango, Q. Pablo, M. Queralt, R. Núñez, E. Álvarez, José Antonio Vinagre Romero, José Luis Poveda, M.T. Álvarez, F.J. Badia, M. Tort, V. Luís, and R. Perez-Santamarina

Subjects
Emicizumab, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Medicine, Severe haemophilia A, business, Multiple-criteria decision analysis, Intensive care medicine, Value (mathematics)
Published
2019

5. Cost–Utility Analysis of Antihemophilic Factor Rfviii-Fs for Secondary Prophylaxis Vs on-Demand Therapy In Severe Haemophilia A In Italy

Author

Mondher Toumi, A D'Ausilio, A Aiello, S Amoresano, A Coppola, and A Tagliaferri

Subjects
medicine.medical_specialty, Cost–utility analysis, business.industry, On demand, Health Policy, medicine, Public Health, Environmental and Occupational Health, Antihemophilic factor, Severe haemophilia A, Secondary prophylaxis, Intensive care medicine, business, health care economics and organizations
Published
2015
Full Text
View/download PDF

10. Cost-Utility of Prophylaxis VS. On-Demand Treatment In Severe Haemophilia A Patients

Author

R Spendar, Zahra Gharibnaseri, Abdol Majid Cheraghali, Peyman Eshghi, Roya Ravanbod, J. Khedmati, and Majid Davari

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, On demand treatment, 030220 oncology & carcinogenesis, Cost utility, medicine, Severe haemophilia A, Intensive care medicine, business
Published
2016

13. PHM1 COST-EFFECTIVENESS OF REGULAR CONTINUOUS PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A

Author

A Gringeri, Lorenzo G. Mantovani, Monzini, and S Ravera

Subjects
medicine.medical_specialty, Pediatrics, Adult patients, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Severe hemophilia A, humanities, Surgery, Medicine, Severe haemophilia A, Session (computer science), business, Prophylactic treatment
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results